GlassScriptPhysician profile
Debby Lynn Maloney
NPI 1851965925
$2,862.88
in general payments reported to CMS, 2019-2025
38 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $454 · 2023: $1,042 · 2024: $776 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.91 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $360.95 | 2021-2025 | |
| Biogen, INC. | $293.66 | 2022-2024 | Vumerity, Tysabri |
| Pfizer INC. | $198.32 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $174.28 | 2022-2024 | Ingrezza, Ongentys |
| Tg Therapeutics, INC. | $168.68 | 2024 | |
| Eisai INC. | $142.37 | 2023-2024 | |
| Emd Serono, INC. | $136.92 | 2022-2024 | Mavenclad |
| Genzyme Corporation | $113.49 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $112.74 | 2022-2024 | Austedo Xr, Ajovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.20 | 2022-2025 | Caplyta |
| Ucb, INC. | $86.05 | 2023-2024 | Fintepla |
| Nestle Healthcare Nutrition INC. | $83.15 | 2021-2022 | |
| Novo Nordisk INC | $81.33 | 2021-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $71.04 | 2021-2025 | Airsupra, Farxiga |
| Neurelis, INC. | $65.82 | 2022-2024 | Valtoco |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debby Maloney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.